NCT00704730 · BASELINE

Baseline characteristics

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer · Source last updated 2021-04-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
219
group Id
BG001
value
111
group Id
BG002
value
330
units
Participants

groups

description
XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily
id
BG000
title
XL184 (Cabozantinib)
description
oral capsules once daily
id
BG001
title
Placebo
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
172
group Id
BG001
value
86
group Id
BG002
value
258
title
Between 18 and 65 years
measurements
group Id
BG000
value
47
group Id
BG001
value
25
group Id
BG002
value
72
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
13.33
value
54.4
group Id
BG001
spread
13.39
value
53.8
group Id
BG002
spread
13.33
value
54.2
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
68
group Id
BG001
value
41
group Id
BG002
value
109
title
Female
measurements
group Id
BG000
value
151
group Id
BG001
value
70
group Id
BG002
value
221
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
1
group Id
BG002
value
9
title
Austria
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
5
group Id
BG002
value
12
title
Belgium
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
3
group Id
BG002
value
7
title
Brazil
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
2
group Id
BG002
value
8
title
Canada
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Chile
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Denmark
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
5
group Id
BG002
value
30
title
France
categories
measurements
group Id
BG000
value
15
group Id
BG001
value
10
group Id
BG002
value
25
title
Germany
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
Greece
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Portugal
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
1
group Id
BG002
value
6
title
India
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
4
group Id
BG002
value
9
title
Israel
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Complete source fields

denoms

counts
group Id
BG000
value
219
group Id
BG001
value
111
group Id
BG002
value
330
units
Participants

groups

description
XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily
id
BG000
title
XL184 (Cabozantinib)
description
oral capsules once daily
id
BG001
title
Placebo
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
172
group Id
BG001
value
86
group Id
BG002
value
258
title
Between 18 and 65 years
measurements
group Id
BG000
value
47
group Id
BG001
value
25
group Id
BG002
value
72
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
13.33
value
54.4
group Id
BG001
spread
13.39
value
53.8
group Id
BG002
spread
13.33
value
54.2
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
68
group Id
BG001
value
41
group Id
BG002
value
109
title
Female
measurements
group Id
BG000
value
151
group Id
BG001
value
70
group Id
BG002
value
221
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
1
group Id
BG002
value
9
title
Austria
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
5
group Id
BG002
value
12
title
Belgium
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
3
group Id
BG002
value
7
title
Brazil
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
2
group Id
BG002
value
8
title
Canada
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Chile
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Denmark
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
5
group Id
BG002
value
30
title
France
categories
measurements
group Id
BG000
value
15
group Id
BG001
value
10
group Id
BG002
value
25
title
Germany
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
Greece
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Portugal
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
1
group Id
BG002
value
6
title
India
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
4
group Id
BG002
value
9
title
Israel
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice